Inventiva SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew Obenshain
- Full Time Employees
- 77
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 50 rue de Dijon Daix BF France 21121
- IPO Date
- Feb 15, 2017
- Website
- inventivapharma.com
- Similar Companies
- Business
- Inventiva S.A. (Euronext Paris: IVA; Nasdaq: IVA) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology; its lead product candidate, lanifibranor, a pan-PPAR agonist, advances in the phase 3 NATiV3 trial for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), demonstrating efficacy in resolving NASH without worsening fibrosis, improving fibrosis without worsening NASH, and achieving composite endpoints in prior phase 2b studies; the second clinical asset, odiparcil, targets mucopolysaccharidoses (MPS) by modifying glycosaminoglycan synthesis to promote urinary excretion; earlier-stage programs include preclinical efforts in TGF-beta for idiopathic pulmonary fibrosis, Hippo signaling pathway modulation, and oncology indications such as multiple myeloma and lung cancer. Founded in 2011 and headquartered at 50 rue de Dijon in Daix, France, the company leverages a proprietary discovery engine with a library of over 240,000 compounds, expertise in nuclear receptors, transcription factors, and epigenetic modulation, and partnerships including collaborations with AbbVie, Boehringer Ingelheim, Sino Biopharm, and Hepalys Pharma. Recent developments include the October 2025 launch of a $100 million at-the-market (ATM) equity offering program through Piper Sandler to fund lanifibranor development and operations, a November 2025 announcement of a $125 million public offering of American Depositary Shares (ADSs) representing new ordinary shares, and a strategic pipeline prioritization focusing clinical resources on lanifibranor while suspending odiparcil advancement and reviewing options for its future.
Company News
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14
Inventiva (NASDAQ:IVA) Stock Price Up 5.5% – Time to Buy?
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva Q2 Earnings Call Highlights
Inventiva Q2 Earnings Call Highlights
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹